Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian Sells 134,713 Shares

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.27 on Thursday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The firm’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $3.47. Syros Pharmaceuticals, Inc. has a twelve month low of $0.18 and a twelve month high of $8.17. The firm has a market cap of $7.18 million, a P/E ratio of -0.09 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the business earned ($1.35) EPS. As a group, research analysts expect that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on SYRS shares. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and set a $5.00 price objective (down previously from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, StockNews.com assumed coverage on shares of Syros Pharmaceuticals in a report on Thursday, November 21st. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Syros Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $3.33.

Hedge Funds Weigh In On Syros Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals in the third quarter valued at about $34,000. Virtu Financial LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at about $64,000. Acadian Asset Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at about $91,000. Certuity LLC acquired a new position in Syros Pharmaceuticals in the second quarter valued at about $109,000. Finally, Kennedy Capital Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at about $2,166,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.